Annual report pursuant to Section 13 and 15(d)

INCOME TAXES

v3.21.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 11 - INCOME TAXES

 

Income tax expense differs from the statutory amounts for each of the following years:

 

    2020     2019  
    For the years ended December 31,  
    2020     2019  
Income taxes at U.S. statutory rate   $ (17,689,000 )   $ (16,020,000 )
Current year reserve     12,020,000       15,976,000  
Expenses not deductible     5,669,000       44,000  
Total tax expense   $ -     $ -  

 

Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows:

 

    December 31, 2020     December 31, 2019  
Deferred tax assets (liabilities):                
Net operating loss carryforwards   $ 61,062,000     $ 50,802,000  
General business credit carryforwards     4,398,000       3,939,000  
State credits     2,857,000       2,934,000  
Property, equipment and goodwill     8,000       (28,000 )
Stock options     9,551,000       7,960,000  
Deferred revenue     62,000       62,000  
Intangible assets     312,000       1,625,000  
Other     70,000       28,000  
Gross deferred tax assets     78,320,000       67,322,000  
Valuation allowance     (78,320,000 )     (67,322,000 )
Net deferred taxes   $ -     $ -  

 

 

As of December 31, 2020, we had approximately $290.8 million of net operating loss carryforwards and approximately $4.4 million of general business credit carryforwards. These carryforwards expire as follows:

 

    Net operating
loss carryforwards		     General business credit
carryforwards		  
2021   $ 5,378,000     $ 56,000  
2022     8,230,000       431,000  
2023     5,434,000       362,000  
2024     8,711,000       287,000  
2025     2,370,000       182,000  
Thereafter     97,576,000       3,080,000  
    $ 127,699,000     $ 4,398,000  

 

As of December 31, 2020, we had approximately $163.1 million of net operating loss carryforwards that do not expire and can be carried forward indefinitely.

 

We acquired MacroChem Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both of these corporations were loss-making entities at the time of acquisition. As a result, the net operating losses related to those acquisitions may be subject to annual limitations as well.